Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

322
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
322
Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

18
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
18
Pharmacokinetic–Pharmacodynamic Relationship: Model Components01:14

Pharmacokinetic–Pharmacodynamic Relationship: Model Components

21
Pharmacokinetic-pharmacodynamic (PK–PD) modeling is essential in drug development and clinical pharmacology. It provides a quantitative framework to predict drug behavior and response over time. This approach integrates pharmacokinetics (PK), which describes the drug's absorption, distribution, metabolism, and excretion, with pharmacodynamics (PD), which characterizes the drug’s biological effects and mechanisms of action.The disposition kinetics of a drug determine its plasma...
21
Pharmacokinetic–Pharmacodynamic Relationship: Exposure, Response and Effect01:26

Pharmacokinetic–Pharmacodynamic Relationship: Exposure, Response and Effect

27
The pharmacokinetic-pharmacodynamic (PK-PD) relationship describes the intricate link between drug exposure, efficacy, and toxicity, forming the foundation for optimal dosing regimens. This relationship uses mathematical modeling to characterize drug concentration-effect dynamics, ensuring precise therapeutic outcomes.Exposure represents the pharmacokinetic aspect of the PK-PD relationship, denoting the drug amount that elicits a biological response. It is typically quantified by administered...
27
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

822
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
822
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

19
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
19

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enantioselective Pharmacokinetics of Venlafaxine in the Presence of CYP2D6 Inhibition: A Population Parent-Metabolite Modeling Approach.

Journal of clinical pharmacology·2026
Same author

Pain and treatment outcomes after initiating methadone vs buprenorphine among medicare patients with opioid use disorder and comorbid chronic pain: A target trial emulation.

PLoS medicine·2026
Same author

Translational Model to Predict Lung and Prostate Distribution of Levofloxacin in Humans.

Pharmaceutics·2026
Same author

Predictive factors of surgical difficulty in laparoscopic cholecystectomy in a secondary hospital.

Acta cirurgica brasileira·2026
Same author

Polymorphisms in the proprotein convertase subtilisin/kexin type 9 gene in clinically diagnosed patients with familial hypercholesterolemia.

Revista da Associacao Medica Brasileira (1992)·2025
Same author

A Quantitative Systems Pharmacology (QSP) Model of Acute Hepatitis B Virus Infection: Mechanistic Insights and Foundations for Future Extensions.

CPT: pharmacometrics & systems pharmacology·2025

Related Experiment Video

Updated: Feb 17, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.1K

Explaining clinically important variability in response to simvastatin treatment using a PBPK/PD approach.

Wonho Kang1, Ana Carolina Conchon Costa1, Jose Ivan Marques Medeiros2

  • 1Center for Pharmacometrics and Systems Pharmacology, College of Pharmacy, University of Florida, Orlando, Florida, USA.

Journal of Clinical Pharmacology
|February 16, 2026
PubMed
Summary

Optimizing simvastatin (SV) dosing requires considering liver exposure to its active form, simvastatin hydroxy acid (SVA). Physiological factors like obesity, not just genetics, impact SVA levels and cholesterol reduction.

Keywords:
PBPKgastric bypasssimvastatin hydroxy acid

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.2K
A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

10.3K

Related Experiment Videos

Last Updated: Feb 17, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.1K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.2K
A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

10.3K

Area of Science:

  • Pharmacology
  • Pharmacokinetics
  • Systems Biology

Background:

  • Optimal simvastatin (SV) dosing balances efficacy and safety, but plasma levels don't always reflect intrahepatic exposure of the active form, simvastatin hydroxy acid (SVA).
  • Hepatocyte uptake via OATP1B1 transporter (SLCO1B1) and metabolism by CYP3A4 influence SVA pharmacokinetics.
  • Obesity and Roux-en-Y gastric bypass (RYGB) surgery can alter drug disposition and enzyme activity, affecting hepatic drug exposure.

Purpose of the Study:

  • To evaluate gene-drug and disease-drug interactions affecting SVA pharmacokinetics.
  • To optimize SV dosing by linking intrahepatic unbound SVA concentration to LDL-cholesterol (LDL-C) reduction.
  • To utilize a physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) modeling approach.

Main Methods:

  • Physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) modeling was employed.
  • Simulations were conducted across various doses, SLCO1B1 genotypes, and populations.
  • The study linked intrahepatic unbound SVA concentration to LDL-C reduction.

Main Results:

  • SLCO1B1 c.521T>C variation impacted plasma SVA exposure but not hepatic SVA exposure.
  • Obese individuals showed higher plasma and hepatic SVA exposure compared to non-obese individuals.
  • A 20 mg SV dose achieved 30-49% LDL-C reduction in obese subjects regardless of SLCO1B1 genotype, while non-obese subjects may need 40 mg.

Conclusions:

  • Systemic drug concentration and SLCO1B1 genotyping alone are insufficient for predicting statin response.
  • Integrating genetic and physiological variability into a PBPK/PD framework is crucial for optimizing SV doses.
  • Personalized dosing strategies are needed for diverse populations to achieve optimal simvastatin efficacy and safety.